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esponsibility of Xi’Abstract A sensitive and selective liquid chromatography–tandem mass spectrometric (LCMS/MS)
method was established to determine 2-oxo-clopidogrel, a crucial intermediate metabolite in human
plasma. A chromatographic separation was performed on a Sapphire C18 column following a liquid–liquid
extraction sample preparation with methyl t-butyl ether. Detection was carried out on a triple quadrupole
mass spectrometer operated in multiple reaction monitoring (MRM) with an electrospray ionization (ESI)
mode. The method was validated in terms of speciﬁcity, accuracy, precision and limit of quantiﬁcation.
The calibration curves ranged from 0.50 to 50.0 ng/mL with good linearity. The stability was fully
validated with addition of 1,4-dithio-DL-threitol (DTT) into the plasma sample prior to and in the
preparation procedure. The validated method was proved to be suitable for use in pharmacokinetic study
after single oral administration of 75 mg clopidogrel tablets in human subjects, which could make
contribution to intensive study of the clinical drug–drug interactions of clopidogrel and individual
treatment.
& 2014 Xi’an Jiaotong University. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
Clopidogrel, like prasugrel and ticlopidine, is a member of the
thienopyridine class. As prodrugs, the responses to these thienopyr-
idine prodrugs depend on exposure to their respective active
metabolites, which are signiﬁcantly attributed to thiolactone inter-
mediate concentration [1]. For clopidogrel, a large inter-individualsity. Production and hosting by Else
4
5 83271090.
(M. Song).
an Jiaotong University.variability of platelet aggregation was observed in patients and this
variation was relevant to CYP2C19 genetic polymorphisms, which
was involved in CYP-dependent metabolism [2]. Clopidogrel is
metabolized through two major pathways. Approximately 85% of a
clopidogrel dose is hydrolyzed rapidly to form an inactive acid
metabolite [3,4], which will conjugate to the inactive acyl glucur-
onide [5]. A small portion of clopidogrel is oxidized to 2-oxo-
clopidogrel (Fig. 1) by CYP3A, CYP2B6 and CYP2C19, followed
by the formation of an active metabolite by CYP2C19 or by PON1
[2]. Compared with prasugrel, little metabolism of clopidogrel to the
thiolactone has been observed [6], which led to less potent andvier B.V. All rights reserved.
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fore, the thiolactone intermediate 2-oxo-clopidogrel plays an
important role in clopidogrel metabolism. To predict human
response to clopidogrel and make individualized treatment and to
make intensive research study of the clinical drug–drug interactions
of clopidogrel on the basis of the fact that 2-oxo-clopidogrel inhibits
the activity of CYP2C19 strongly [8], the detailed pharmacokinetics
of 2-oxo-clopidogrel needs to be revealed.
Some LCMS/MS assays for quantiﬁcation of clopidogrel or
its metabolites have been reported. Several methods were devel-
oped to simultaneously quantify clopidogrel and its main metabo-
lite clopidogrel carboxylic acid [9–14]: one work was established
to quantify clopidogrel and its derivatized active thiol metabolite
[15]; another study was reported for the simultaneous determina-
tion of clopidogrel, its main metabolite and derivatized isomers of
thiol metabolite [16]; and one paper presented the simultaneous
quantiﬁcation of clopidogrel, its main metabolite and the newly
described acyl glucuronide metabolite [17]. To the best of our
knowledge, no methods have been reported for quantiﬁcation of
2-oxo-clopidogrel in human plasma yet. However, the high
activity of thiolactone poses great challenge for the establishment
of analytic method. For the lucubration of clopidogrel metabolism
and individual treatment, this study focused on developingS
N
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COOCH3
S
N
C
O
Clopidogrel 2-Oxo-Cl
Fig. 1 Active metabolic p
Fig. 2 Product ion spectra of (A)an LCMS/MS method [18,19] to determine the concentration
of 2-oxo-clopidogrel. To achieve the goal, the method was
validated and applied to a pharmacokinetic study.2. Materials and methods
2.1. Chemicals and reagents
Plavix tablets were purchased from Sanoﬁ Pharmaceuticals Co.,
Ltd. (Hangzhou, China). 2-Oxo-clopidogrel hydrochloride was
offered by Absin Bioscience Inc. (Shanghai, China). Mifepristone
(Internal Standard, IS) was supplied by Xianju Pharmaceutical
Co., Ltd. (Zhejiang, China). DTT (purity Z98%) was purchased
from Sinopharm Chemical Reagent Co., Ltd. (Shanghai, China).
Acetonitrile and methyl tert-butyl ether (MTBE) of HPLC/Spectro
grade were obtained from Tedia Company Inc. (Fairﬁeld, OH,
USA). Other chemicals were all of analytical grade and purchased
from Nanjing Chemical Reagent Co., Ltd. (Nanjing, China), and
de-ionized water was generated with a Hydro-Reverse Osmosis
system (Durham, NC, USA) connected to a Milli-Q UV Plus
purifying system (Billerica, MA, USA).l
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2-oxo-clopidogrel and (B) IS.
Y.-H. Li et al.142.2. Instrumentation
A Waters Alliance 2695 LC system with a column oven (Milford,
MA, USA) was coupled with a Micromass Quattromicro tandem
MS system (Micromass, Manchester, UK), which was equipped
with an ESI source and operated with MassLynx 4.0 software.
2.3. Chromatographic and MS/MS conditions
HPLC separation was carried out on a Sapphire C18 analytical
column (250 mm  4.6 mm 5 μm) with mobile phase
A-acetonitrile and B-water containing 0.1% (v/v) formic acid
(A:B¼95:5) at a ﬂow rate of 1 mL/min and the column
temperature was maintained at 40 1C. The sample injection
volume was 30 μL and the analytical run time was 5.5 min. The
eluent from the HPLC column was introduced directly to the
Micromass using ESI source in the positive ion mode.
The Micromass Quantum parameters were optimized and set as
follows: source temperature 120 1C, nitrogen desolvation gas
370 1C with a ﬂow rate of 500 L/h, cone voltage at 24 V and
28 V, and the collision energies at 17 eV and 21 eV for 2-oxo-
clopidogrel and mifepristone, respectively. Quantiﬁcations were
performed by using MRM with ion transitions of m/z 338.1-
183.1 for 2-oxo-clopidogrel and m/z 430.0-372.0 for mifepris-
tone. The product ion spectra of these analytes are shown in Fig. 2.
2.4. Preparation of stock and working standard solutions
Stock solutions of 2-oxo-clopidogrel (10 μg/mL) and the IS
(1 mg/mL) were separately prepared in acetonitrile, and then
stored at 20 1C. Appropriate dilutions were made in acetonitrile
to produce a series of working standard solutions of 5, 10, 20, 80,
100, 200, 300, 400 and 500 ng/mL for 2-oxo-clopidogrel and
10 μg/mL for IS. All the working standard solutions for 2-oxo-
clopidogrel and IS were freshly prepared when needed.
2.5. Sample preparation
An aliquot of 400 μL human blank plasma in a 10 mL glass
centrifugation tube containing 50 μL DTT (0.02 M) was spiked
with 40 μL of 2-oxo-clopidogrel and 40 μL of the IS solutions
(10 μg/mL). After 100 μL of HCl (0.05 M) was added and the
solution was vortex-mixed for 10 s, 1.5 mL MTBE was added and
vortex-mixed for 3 min. An aliquot of 1.2 mL of the supernatant
was taken after centrifuged at 2000g for 10 min and 50 μL DTT
(0.02 M) was added again, and then, evaporated to dryness under
vacuum. The residual was reconstituted in 150 μL of a mobile
phase of A-acetonitrile and B-water containing 0.1% (v/v) formic
acid (95:5) and centrifuged at 16,000g for 10 min. Then, 30 μL
aliquot was injected onto the LCMS/MS system. For optimal
stability, the auto-sampler temperature was set at 4 1C.
2.6. Method validation
The LCMS/MS method was validated according to the Food
and Drug Administration guidelines for bioanalytical method
validation. The method was validated in terms of selectivity,
linearity, the lower limit of quantiﬁcation (LLOQ), accuracy,
precision, extraction efﬁciency, matrix effect and stability.
Selectivity was performed using six different sources of blank
plasma. They were processed by the same extraction procedureand analyzed to determine the extent to which endogenous plasma
components may contribute to the interference at the retention time
of 2-oxo-clopidogrel and the IS.
Linearity of the calibration curves assessed in duplicate on three
consecutive days was estimated for the ratio of peak area of 2-oxo-
clopidogrel to that of the IS as a function of the concentration
of 2-oxo-clopidogrel covering the range of 0.5050.0 ng/mL in
plasma using 1/x2 as a weighting factor (where x is the
concentration of 2-oxo-clopidogrel). The correlation coefﬁcients
of the calibration curves had been determined. The equations of
calibration curves were used to calculate concentration of 2-oxo-
clopidogrel in human plasma.
LLOQ was determined by the method with the accuracy
(expressed as percentage of the nominal concentration) within
80–120% and precision (expressed as relative standard deviation,
%RSD) not exceeding 20%. The intra-day accuracy and precision
were evaluated by analyzing six replicates at low QC (1.00 ng/mL),
medium QC (20.0 ng/mL), and high QC (40.0 ng/mL) levels of the
same day. The inter-day accuracy and precision were determined by
analyzing the respective QCs in three different days.
Stability of 2-oxo-clopidogrel in plasma was evaluated at
concentrations of 2.00 and 50.0 ng/mL in three replicates for each
concentration under different storage conditions. Sample stability
was tested by analyzing QCs after three freeze-thaw cycles as well
as short-term storage (plasma samples with DTT added and post-
preparative samples kept at room temperature for 8 h) and long-
term storage (45 days at 80 1C). Moreover, the stability of
2-oxo-clopidogrel in post-preparative samples in the auto-sampler
at 4 1C for 24 h and stability of stock solutions at 20 1C for
2 months were also analyzed.
The extraction efﬁciency was evaluated using plasma samples
of the calibration curves at concentrations of 1.00, 20.0 and
40.0 ng/mL. The reference samples of extraction efﬁciency were
prepared by adding working solutions of 2-oxo-clopidogrel and IS
to blank plasma extracts. To investigate the matrix effect, the
reference samples of matrix effect were compared to reference
solutions without matrix.
2.7. Application of the method to pharmacokinetic study
A pharmacokinetic study was conducted in eight human subjects.
This study complied with the revised Declaration of Helsinki for
biomedical research involving human subjects and the rules of
good clinical practice (GCP), and was approved by the Research
Ethics Board of Xijing Hospital. Informed consent was obtained
from all human subjects. After the human subjects were recruited,
each was administered a tablet of Plavix containing 75 mg
clopidogrel with 250 mL water within half an hour after breakfast.
Ethylenediamineteraacetic acid (EDTA) solution was used as an
anti-coagulant and DTT was used as a reducing agent. Three
milliliters venous blood was collected before Plavix administration
and at 0.5, 1, 2, 2.5, 3, 3.5, 6, 8, 12 and 24 h after dosing. The
plasma samples were separated by centrifugation at 16,000g for
10 min and frozen at 80 1C until assayed for 2-oxo-clopidogrel.3. Results and discussion
3.1. Sample preparation and LCMS/MS analysis
2-Oxo-clopidogrel has the tendency to be oxidized to the sulfoxide
or sulfone without a reducing agent owing to the nature of sulfur
Quantiﬁcation of 2-oxo-clopidogrel in human plasma 15atom in 2-oxided thiolactone. Our study showed that it was
necessary to add a reducing agent to maintain 2-oxo-clopidogrel
in an un-oxidized state during sample collection and preparation.
At ﬁrst, 2-oxo-clopidogrel could not be detected even in standard
samples without any antioxidant added in plasma. Then several
antioxidants were tested, and ascorbate showed some antioxidant
capability. However, the data were still not stable enough, which
were the same as what was found in the homocysteine thiolactione
stability study [20]. For the thiolactone bioanalytic assay, it was
reported that adding DTT in sample preparation process could
make the analytes erdosteine and its metabolite stable [21]. DTT
was tried, and then no signiﬁcant degradation was found in
stability test. However, preliminary experiment data showed that
2-oxo-clopidogrel could be oxidized to a certain extent if not
adding antioxidant immediately after collection or not freezing the
plasma sample right away (date not shown). Consequently, to
ensure the stability of 2-oxo-clopidogrel during sample processing
and storage, the antioxidant DTT was added into the tubes prior to
sample collection.
The liquid chromatography method development began with
optimizing the mobile phase composition and column type. The
Sapphire C18 column (250 mm  4.6 mm 5 μm) provided good
selectivity and peak shape for both 2-oxo-clopidogrel and IS, as
compared to other columns. The mobile phase consisting of
A-acetonitrile and B-water containing 0.1% (v/v) formic acid
(A:B¼95:5) with a ﬂow rate of 1 mL/min was found to be suitable
during LC optimization. The retention times for 2-oxo-clopidogrel
and IS were observed at 3.8 min and 5.0 min, respectively. Mifepris-
tone was chosen as the internal standard for the determination ofFig. 3 LCMS/MS of (A) Blank plasma extract, (B) Spiked LLOQ (0.5
Plasma sample collected from a subject at 2 h elapsed from administrati
mifepristone).2-oxo-clopidogrel in human plasma thanks to its similar polarity and
stable ionization rate without interfering.
In the MS method development, full-scan mass spectra of both
2-oxo-clopidogrel and IS were obtained in the positive ion mode
with ESI source. Quantiﬁcations were performed by using MRM
with ion transitions of m/z 338.1-183.1 for 2-oxo-clopidogrel
and m/z 430.0-372.0 for IS, which could further improve the
sensitivity.
3.2. Method validation
3.2.1. Selectivity
Fig. 3 depicts representative chromatograms resulting from the
LCMS/MS analysis of extracts of 400 μL plasma from: (A)
blank plasma sample, (B) spiked LLOQ (0.50 ng/mL, tR¼3.8
min) and IS (1 μg/mL, tR¼5.0 min), and (C) plasma sample
collected from a subject at 2 h elapsed from administration of a
tablet with 75 mg clopidogrel. Furthermore, no carryover was
observed for 2-oxo-clopidogrel or IS by running a blank sample
following the upper limit of quantiﬁcation (ULOQ: 50.0 ng/mL for
2-oxo-clopidogrel), without detecting 2-oxo-clopidogrel or IS peak
at their respective retention.
3.2.2. Linearity
The calibration curve ranged from 0.50 to 50.0 ng/mL, with a typical
equation for the calibration curve being y¼0.00648xþ0.000257
(r40.997). For each calibration standard level, the concentration
was back calculated from the calibration equation. The mean accuracyng/mL, tR¼3.8 min) and mifepristone (1 μg/mL, tR¼5.0 min), and (C)
on of 75 mg clopidogrel(6.50 ng/mL 2-oxo-clopidogrel and 1 μg/mL
Y.-H. Li et al.16and precision for back calculated concentrations of each standard
calculated from calibration curves are tabulated in Table 1.3.2.3. LLOQ
Independent LLOQ experiments were performed by preparing the
LLOQ in six different lots of plasma. The LLOQ was 0.50 ng/mL
of 2-oxo-clopidogrel. The accuracy for back calculated concentra-
tions of LLOQ is tabulated in Table 2.3.2.4. Accuracy and precision
The intra- and inter-day accuracies were 102.7–105.8% and 97.2–
106.0%, respectively, and the intra- and inter-day assay precisions
were 4.0–5.8% and 6.4–14.2%, respectively.Table 1 The accuracy and precision from calibration
curvesa.
Nominal conc.
(ng/mL)
Mean accuracy (%) Precision
(%RSD)
0.50 102.7 2.9
1.00 93.0 3.4
2.00 104.6 7.9
8.00 97.0 11.0
10.0 96.2 6.1
20.0 100.5 2.5
30.0 102.8 7.5
40.0 103.3 6.7
50.0 96.1 4.3
an¼6.
Table 2 The accuracy and precision from LLOQsa.
LLOQ conc.
(ng/mL)
Measured conc.
(ng/mL)
Accuracy (%)
0.50 0.584 116.8
0.50 0.518 103.6
0.50 0.539 107.8
0.50 0.570 114.0
0.50 0.575 115.0
0.50 0.525 105.0
an¼6.
Table 3 Stability of 2-oxo-clopidogrel in human plasma.
Stability experiments Mean measured conc. (n¼
La (ng/mL) H
Long-term stability (45 days) 1.96 5
Freeze-thaw stability (3rd cycles) 1.84 5
Bench top stability(8 h) 2.29 5
Post-preparative stability(8 h) 2.12 4
Auto-sampler stability(24 h) 2.25 4
aL means low concentration in human plasma (nominal concentration is
bH means high concentration in human plasma (nominal concentration i3.2.5. Extraction recovery and matrix effect
The extraction recoveries in human plasma were 92.573.9%,
114.073.5% and 110.977.8% at 1.00, 20.0 and 40.0 ng/mL
(n¼6), respectively. For the IS, the extraction recovery at 1 μg/mL
was 111.478.2% (n¼18). The mean matrix effects of 2-oxo-
clopidogrel from six different plasma sources at three concentra-
tion levels were 63.7%, 71.6% and 63.7%, respectively. For the IS,
the matrix effect was 77.079.4% (n¼18). The extraction recov-
ery and matrix effect for 2-oxo-clopidogrel were consistent when
examined repeatedly at the same concentration or at variant
concentrations.3.2.6. Stability
Stock solutions of 2-oxo-clopidogrel and IS in acetonitrile were
stable at 20 1C for at least 2 months. In human plasma, no
signiﬁcant degradation of 2-oxo-clopidogrel occurred under the
following conditions: three freeze–thaw cycles, plasma samples
with DTT on the bench top at room temperature for 8 h and at
80 1C for 45 days, post-preparative samples at room temperature
for 8 h, in auto-sampler at 4 1C for 24 h. The stability test results
are displayed in Table 3.3.3. Application of the developed LCMS/MS method
In order to verify the sensitivity and selectivity of the developed
method in a real-time situation, the method described in this paper
was applied to a human pharmacokinetic that generated over 8
human plasma samples. After oral administration of a tablet
containing 75 mg clopidogrel to the eight subjects, the mean
plasma concentration-time proﬁle of 2-oxo-clopidogrel is depicted
in Fig. 4 and the pharmacokinetic data of 2-oxo-clopidogrel are
presented in Table 4.4. Conclusion
The LCMS/MS method has been successfully set up for the
pharmacokinetic study of Plavix tablets in human subjects. The
established LCMS/MS method is sensitive for plasma 2-oxo-
clopidogrel determination and suitable for the pharmacokinetic
study of Plavix tablets. Because of the relative short chromato-
graphic run time (5.5 min), the method is easy to follow and can
be adopted for clinical drug monitoring.3) Mean % RE from theoretical
b (ng/mL) La(ng/mL) Hb (ng/mL)
1.9 2.3 3.8
0.9 8.0 1.8
2.9 14.5 5.8
8.1 6.0 3.8
7.4 12.5 5.2
2.00 ng/mL).
s 50.0 ng/mL).
Fig. 4 Plasma concentration-time proﬁle (mean7SD, n¼8) of
2-oxo-clopidogrel after an administration of 75 mg Plavix in human
subjects.
Table 4 Pharmacokinetic data of 2-oxo-clopidogrel after
their oral administration in 8 subjects.
Parameter 2-Oxo-clopidogrel
Cmax (ng/mL) 6.870.9
Tmax (h) 1.873.4
t1/2 (h) 65740
AUC0–24(ng h/mL) 89710
AUC01 (ng h/mL) 3837180
Cmax: maximum plasma concentration.
Tmax: time point of maximum plasma concentration.
t1/2: half life of drug elimination during the terminal phase.
AUC0–24: area under the plasma concentration–time curve from
zero to 24 h.
AUC0–1: area under the plasma concentration–time curve from
zero hour to inﬁnity.
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